ReviewBiochemistry and biophysics reports2026
One-carbon metabolism and cardiovascular disease: Molecular mechanisms, genetic influences, and epigenetic regulation.
Review in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperhomocysteinemia, characterized by elevated levels of circulating homocysteine, has emerged as a significant risk factor for cardiovascular disease (CVD). This literature review explores the multifactorial relationship between one-carbon metabolism (OCM) and cardiovascular health, focusing on the biological mechanisms that link OCM disruptions to vascular dysfunction and disease development. Emphasis is placed on the biochemical interplay between genetic polymorphisms, nutritional deficiencies (particularly B vitamins and folate), and epigenetic processes including DNA methylation, histone modifications, and non-coding RNAs. These alterations can affect gene expression, endothelial integrity, lipid metabolism, and inflammatory pathways, thereby increasing the risk of atherosclerosis, hypertension, and other CVDs. Promising therapeutic interventions-such as targeted supplementation and epigenetic-modulating strategies-are discussed as future tools for prevention and personalized treatment of cardiovascular disorders.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.